Back to Search
Start Over
Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
- Source :
- BioMed Research International; 10/23/2020, p1-9, 9p
- Publication Year :
- 2020
-
Abstract
- Immunotherapy, especially based on chimeric antigen receptor (CAR) T cells, has achieved prominent success in the treatment of hematological malignancies. However, approximately 30-50% of patients will have disease relapse following remission after receiving CD19-targeting CAR-T cells, with failure of maintaining a long-term effect. Mechanisms underlying CAR-T therapy inefficiency consist of loss or modulation of target antigen and CAR-T cell poor persistence which mostly results from T cell exhaustion. The unique features and restoration strategies of exhausted T cells (Tex) have been well described in solid tumors. However, the overview associated with CAR-T cell exhaustion is relatively rare in hematological malignancies. In this review, we summarize the characteristics, cellular, and molecular mechanisms of Tex cells as well as approaches to reverse CAR-T cell exhaustion in hematological malignancies, providing novel strategies for immunotherapies. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 23146133
- Database :
- Complementary Index
- Journal :
- BioMed Research International
- Publication Type :
- Academic Journal
- Accession number :
- 146606246
- Full Text :
- https://doi.org/10.1155/2020/8765028